Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

Inclusion Criteria: * Otherwise healthy male and female adolescent subjects with moderate to severe acne vulgaris on a 5 point IGA scale * At least 20 total inflammatory lesions (papules and pustules), and at least 20 total non-inflammatory lesions (open and closed comedones) on the face, chest, back, and shoulders * Age 9-16 years, 11 months inclusive * Subjects with methemoglobin level less than 3% at Screening and Baseline by pulse co-oximeter Exclusion Criteria: * Subjects with any other acne-like dermatological conditions such as severe, recalcitrant nodulocystic acne, acne conglobata, acne fulminans, acne secondary to medications or other medical conditions, perioral dermatitis, clinically significant rosacea, or gram-negative folliculitis; * Any subject with skin disorders of an acute or chronic nature including psoriasis, eczema, tinea versicolor, etc. * Subjects who reside in a dwelling that relies on well water for a primary drinking source * Subjects with facial hair (beards, mustaches, etc.), tattoos or other facial markings that would interfere with assessments and study drug application * Transgender subjects receiving hormone supplement (male to female or female to male) * Subjects with a previous history of methemoglobinemia or taking medications known to be associated with methemoglobinemia * Subjects with a known history of HIV, hepatitis, or other blood-borne pathogens * Females who are pregnant, planning a pregnancy or breastfeeding * Subjects previously treated with NVN1000 Gel / SB204